Sexual and hormonal health
Premature ejaculation
Earlier-than-desired ejaculation with distress differs from erectile dysfunction or low desire. Lifelong and acquired patterns can have different contributors.
Potential benefits explored
Better ejaculatory control and less distress.
PT-141 and kisspeptin are included because they affect sexual-response research, but that does not show they delay ejaculation. This is a weakly supported extension that should remain visible as such.
Practical interpretation
Assess the pattern, anxiety and accompanying ED; behavioural, topical and diagnosis-appropriate medication options have more direct relevance.
Meaningful outcomes: Control, distress and relationship impact.
Compare the compounds studied for Premature ejaculation
Members see the full evidence picture for this condition: every compound studied, graded per condition from strong human evidence through to preclinical-only and negative findings, with human and animal results, risks, combination evidence and cited sources — plus how each compound maps to the research materials we list, with live pricing and stock.
Research reference for laboratory materials only. Not medical advice and not a recommendation for human use. Research cut-off: 30 September 2026.